Nasdaq ardx.
Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …16 thg 8, 2021 ... Ardelyx (NASDAQ:ARDX) is trading higher today on below-average volume despite a loss of over 5% on Friday after the company announced worse ...Ardelyx (NASDAQ:ARDX) is another hot penny stock to consider. The biotech stock, which has a market cap of $550 million and is trading at $2.94, could see higher highs.Like Altisource, Ardelyx (NASDAQ:ARDX) is another stock that has performed very well during a time that has been tough for stocks overall.Shares in this pharma firm are up more than fourfold over ...
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...
Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone
Dec 1, 2023 · Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ... WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...18 thg 10, 2023 ... Swing traders and longer-term investors can profit from the significant volatility after approval. To those who haven't bought in, try after the ...Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript (Insider Monkey) Oct-31-23 11:15PM Q3 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) +9.12%. 05:09PM Why Ardelyx Stock Soared Today (Motley Fool) 08:40AM Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates ...
The stock of Ardelyx Inc (NASDAQ: ARDX) has decreased by 0.00 when compared to last closing price of 3.56.Despite this, the company has seen a loss of -11.44% in its stock price over the last five trading days. The Motley Fool reported 2023-10-31 that Ardelyx delivered a surprise profit thanks to strong sales of Ibsrela, its first FDA-approved ...
The stock was up 14.04% at $2.68 in premarket trading. Merck-Eisai's Drug Combo Gets FDA Approval as First-line Treatment For Kidney Cancer. Merck & Co, Inc. (NYSE:MRK) and Eisai Co., Ltd. (OTC ...
Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago.Back to ARDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Dec 4, 2023 · Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ... WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.11 thg 8, 2020 ... Ardelyx, Inc. filed an NDA for its chief asset tenapanor in the control of serum phosphorus in adults with chronic kidney disease on ...
Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.How much is Ardelyx stock worth today? ( NASDAQ: ARDX) Ardelyx currently has 232,137,709 outstanding shares. With Ardelyx stock trading at $4.33 per share, the total value of Ardelyx stock (market capitalization) is $1.01B. Ardelyx stock was originally listed at a price of $14.11 in Jun 19, 2014.Oct 31, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago. These ... Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ... From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ...Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.
Based on analysts offering 12 month price targets for ARDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended …
After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...Nov 20, 2023 · Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ... Oct 18, 2023 · The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ... WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Principal Financial Group Inc. acquired a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 24,269 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. …ARDELYX INC ( ARDX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.
Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.
About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
Oct 17, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ... Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of …3 Penny Stocks to Buy and Hold for the Next 10 Years. 1 month ago. Simply Wall St. 1 week ago. Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, …Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, …Ardelyx, Inc.'s (NASDAQ:ARDX) top owners are individual investors with 53% stake, while20% is held by institutions. Read full article. Simply Wall St. November 8, 2022 at 5:48 AM ...
Based on analysts offering 12 month price targets for ARDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.Feb 19, 2023 · ARDX stock is up more than 270% in the last six months, and analysts are already projecting more gains down the road. The consensus price target for Ardelyx is $6.87, meaning ARDX stock still has ... Instagram:https://instagram. webcashglobal mansionutility stockangus deaton 11 thg 8, 2020 ... Ardelyx, Inc. filed an NDA for its chief asset tenapanor in the control of serum phosphorus in adults with chronic kidney disease on ... ppl corp stock pricetop 20 sandp 500 stocks Ardelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...See historical performance and comparison. View Valuation. Research Ardelyx's (Nasdaq:ARDX) stock price, latest news & stock analysis. Find everything … lockheed martin corp stock WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ...Nov 24, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.